<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00754884</url>
  </required_header>
  <id_info>
    <org_study_id>UIECD-010</org_study_id>
    <nct_id>NCT00754884</nct_id>
  </id_info>
  <brief_title>Calcitonin in the Treatment of Fibromyalgia</brief_title>
  <acronym>CALFI</acronym>
  <official_title>Phase IV Study of Nasal Salmon Calcitonin in the Treatment of Symptoms and Signs of Fibromyalgia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Unidad de Investigacion en Enfermedades Cronico-Degenerativas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Unidad de Investigacion en Enfermedades Cronico-Degenerativas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether nasal administration of salmon calcitonin
      is effective and safe in the treatment of symptoms and signs of primary fibromyalgia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fibromyalgia is a common, chronic musculoskeletal disorder that is characterized by
      widespread pain and tenderness. Fibromyalgia occurs in around 2% of the US general
      population, is more common in women and is associated with substantial morbidity and
      disability. Treatment of fibromyalgia has been disappointing; roughly one-third of patients
      have had a clinically important therapeutic response to medications or no-medicinal
      treatment, event with the newest drugs reported in the literature. Pathophysiology of
      fibromyalgia is unknown, but abnormalities in central neurotransmission might play a role.
      Some studies have shown that salmon calcitonin increases peripheral and central levels of
      endorphins. Increasing endorphins levels may decrease pain. Then, it is feasible that nasal
      administered salmon calcitonin may decrease several of the symptoms and signs of patients
      suffering fibromyalgia.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study drug was not longer available in our country.
  </why_stopped>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Functional status as assessed by the Fibromyalgia Impact Questionnaire (FIQ), a self-report inventory developed to measure health status in patients with fibromyalgia</measure>
    <time_frame>Day 0, Day 14, Day 28 and Day 56</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life as assessed by WHO-DAS II, self-report questionnaire. Dolorimetry will be also used</measure>
    <time_frame>Day 0, Day 14, Day 28 and Day 56</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Fibromyalgia</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 U.I. of intranasal salmon calcitonin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>intranasal saline solution and glycerol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>salmon calcitonin</intervention_name>
    <description>daily intranasal 200 U.I. salmon calcitonin for periods of 14 days at a time</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Miacalcic nasal spray (Novartis Pharmaceutical)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intranasal saline solution plus glycerol</intervention_name>
    <description>daily intranasal (one shot) saline solution plus glycerol for a period of 14 days</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Nasalub</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female patients between 18 and 50 years

          -  Fibromyalgia diagnosis (ACR criteria)

          -  Must be able to apply the nasal medication

          -  Must be able to comply with study visits

          -  Must be able to understand informed consent

          -  Must be able to answer self-administered questionnaires

          -  Must have an active disease(VAS &gt; 60mm)

        Exclusion Criteria:

          -  Comorbid conditions (i.e. hypothyroidism, diabetes mellitus, etc.)

          -  Any disturbance in the nasal tissue

          -  Use of concomitant opioid analgesics

          -  Contraindication to use salmon calcitonin (allergy, hypocalcemia, hypophosphatemia)

          -  Other rheumatic diseases

          -  Diagnosis of major depressive disorder
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cesar R. Ramos-Remus, M.D., MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Attending Rheumatologist HGR45 and Director UIECD</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital General Regional No. 45, IMSS</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44290</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>Burckhardt CS, Clark SR, Bennett RM. The fibromyalgia impact questionnaire: development and validation. J Rheumatol. 1991 May;18(5):728-33.</citation>
    <PMID>1865419</PMID>
  </reference>
  <reference>
    <citation>Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, Tugwell P, Campbell SM, Abeles M, Clark P, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum. 1990 Feb;33(2):160-72.</citation>
    <PMID>2306288</PMID>
  </reference>
  <reference>
    <citation>MacIntyre I, Alevizaki M, Bevis PJ, Zaidi M. Calcitonin and the peptides from the calcitonin gene. Clin Orthop Relat Res. 1987 Apr;(217):45-55. Review.</citation>
    <PMID>3549095</PMID>
  </reference>
  <reference>
    <citation>Sz치nt칩 J, J칩zsef S, Rad칩 J, Juhos E, Hindy I, Eckhardt S. Pain killing with calcitonin in patients with malignant tumours. Oncology. 1986;43(2):69-72.</citation>
    <PMID>3513074</PMID>
  </reference>
  <reference>
    <citation>Mystakidou K, Befon S, Hondros K, Kouskouni E, Vlahos L. Continuous subcutaneous administration of high-dose salmon calcitonin in bone metastasis: pain control and beta-endorphin plasma levels. J Pain Symptom Manage. 1999 Nov;18(5):323-30.</citation>
    <PMID>10584455</PMID>
  </reference>
  <reference>
    <citation>Gennari C. Analgesic effect of calcitonin in osteoporosis. Bone. 2002 May;30(5 Suppl):67S-70S. Review.</citation>
    <PMID>12008161</PMID>
  </reference>
  <reference>
    <citation>Ofluoglu D, Akyuz G, Unay O, Kayhan O. The effect of calcitonin on beta-endorphin levels in postmenopausal osteoporotic patients with back pain. Clin Rheumatol. 2007 Jan;26(1):44-9. Epub 2006 Mar 31.</citation>
    <PMID>16575494</PMID>
  </reference>
  <reference>
    <citation>Wolfe F. The fibromyalgia syndrome: a consensus report on fibromyalgia and disability. J Rheumatol. 1996 Mar;23(3):534-9. Review.</citation>
    <PMID>8832998</PMID>
  </reference>
  <reference>
    <citation>Bessette L, Carette S, Fossel AH, Lew RA. A placebo controlled crossover trial of subcutaneous salmon calcitonin in the treatment of patients with fibromyalgia. Scand J Rheumatol. 1998;27(2):112-6.</citation>
    <PMID>9572636</PMID>
  </reference>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2008</study_first_submitted>
  <study_first_submitted_qc>September 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2008</study_first_posted>
  <last_update_submitted>December 3, 2015</last_update_submitted>
  <last_update_submitted_qc>December 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Unidad de Investigacion en Enfermedades Cronico-Degenerativas</investigator_affiliation>
    <investigator_full_name>Cesar Ramos Remus</investigator_full_name>
    <investigator_title>M.D, Director</investigator_title>
  </responsible_party>
  <keyword>salmon calcitonin</keyword>
  <keyword>endorphins</keyword>
  <keyword>treatment</keyword>
  <keyword>fibromyalgia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Glycerol</mesh_term>
    <mesh_term>Salmon calcitonin</mesh_term>
    <mesh_term>Calcitonin</mesh_term>
    <mesh_term>Calcitonin Gene-Related Peptide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

